undamentalytics Newsletter

Amdocs LTD income statement

In fiscal 2025, Amdocs LTD reported revenue of $4.53bn, down 9.4% on the year before, operating income of $732m (a 16.1% margin) and net income of $565m, or $5.05 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Amdocs LTD: income statement, annual
Fiscal year2013Sept 20132014Sept 20142015Sept 20152016Sept 20162017Sept 20172018Sept 20182019Sept 20192020Sept 20202021Sept 20212022Sept 20222023Sept 20232024Sept 20242025Sept 2025
Revenue3,3463,5643,6443,7183,8673,9754,0874,1694,2894,5774,8885,0054,533
Cost of revenue2,1672,3072,3492,4082,5082,5952,6532,7562,8112,9583,1603,2502,811
Gross profit1,1791,2571,2941,3101,3591,3801,4331,4131,4781,6191,7281,7551,722
Research and development240258255252259277274282313355375361341
Selling, general and administrative419445440465473481492459487529571573506
Operating income482496516483517428570595599665654629732
Interest expense4332234102117233542
Income before tax475490513485513422568583814648636591693
Income tax6367677576678885126999395125
Net income412422446409437354479498688550541493565
Diluted EPS$2.53$2.62$2.85$2.71$2.96$2.47$3.47$3.71$5.32$4.44$4.49$4.25$5.05
Diluted shares (average)163m160m155m150m146m143m137m133m128m122m118m115m111m
EBITDA622658691695732640776793808889782757860

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: DOX vs GENDOX vs PAGSDOX vs ZS

More: Systems Software stocks compared, Technology sector, rankings of US companies

Figures from Amdocs LTD's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Amdocs LTD.